Arabic Arabic English English French French German German
dark

Overview of the FDA Product-Specific Guidance Program

Christine Le from CDER’s Office of Generic Drugs discusses the product-specific guidance (PSG) development processes including how collaborative efforts on how PSGs are prioritized, developed and published. She also shares PSG webpages including the upcoming PSGs for complex generic drug product development webpage as well as an overview on public requests and bioequivalence (BE) comments.

Learn more at https://www.fda.gov/drugs/fda-product-specific-guidances-lighting-development-pathway-generic-drugs-05052021-05052021
_______________________________ 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  

Upcoming Training – https://www.fda.gov/cdersbia   
SBIA Listserv – https://public.govdelivery.com/accounts/USFDA/subscriber/new?topic_id=USFDA_352
SBIA 2021 Playlist – https://youtube.com/playlist?list=PLey4Qe-UxcxYS1MaTusSgyifQDqdeepyD
SBIA LinkedIn – https://www.linkedin.com/showcase/cder-small-business-and-industry-assistance  
SBIA Training Resources – https://www.fda.gov/cderbsbialearn  
Twitter – https://twitter.com/FDA_Drug_Info  
Email – CDERSBIA@fda.hhs.gov  
Phone – (301) 796-6707 I (866) 405-5367

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Panel Discussion

Next Post

Non-Complex Drug Products and Product-Specific Guidances

Related Posts
Total
0
Share